![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (16)
Ruth Milz, Carmela Benson, Karl Knight, Jose Antunes, Dean Najarian, Paola-Maria Lopez Rengel, Steven Wang, Ute Richarz, Srihari Gopal & John M Kane. (2023) The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia. Neuropsychiatric Disease and Treatment 19, pages 531-545.
Read now
Read now
Avijeet S Chopra, Dusica Hadzi Boskovic, Amit Kulkarni & Jeffrey M Cochran. (2023) Cost-Effectiveness of Aripiprazole Tablets with Sensor versus Oral Atypical Antipsychotics for the Treatment of Schizophrenia Using a Patient-Level Microsimulation Modeling Approach. ClinicoEconomics and Outcomes Research 15, pages 375-386.
Read now
Read now
David Taylor, Ramalingam Chithiramohan, Jasdev Grewal, Avirup Gupta, Lars Hansen, Gavin P. Reynolds & Sofia Pappa. (2023) Dopamine partial agonists: a discrete class of antipsychotics. International Journal of Psychiatry in Clinical Practice 27:3, pages 272-284.
Read now
Read now
Heidi C. Waters, Maelys Touya, Soon Nan Wee, Michelle Ng, Simran Thadani, Subina Surendran, Miguel Rentería, A. John Rush, Rashmi Patel, Joydeep Sarkar, Heather M. Fitzgerald & Xue Han. (2023) Psychiatric healthcare resource utilization following initiation of aripiprazole once-monthly: a retrospective real-world study. Current Medical Research and Opinion 39:2, pages 299-306.
Read now
Read now
Jessica J Madera, Pedro Such, Cathy Zhao & Ross A Baker. (2019) Symptomatic stability with aripiprazole once-monthly: efficacy analyses from acute and long-term studies. Neuropsychiatric Disease and Treatment 15, pages 1593-1604.
Read now
Read now
Rosaria Di Lorenzo, Paola Ferri, Michela Cameli, Sergio Rovesti & Chiara Piemonte. (2019) Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting. Neuropsychiatric Disease and Treatment 15, pages 183-198.
Read now
Read now
Richard E Hodgson. (2019)
Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting. ClinicoEconomics and Outcomes Research 11, pages 517-524.
Read now
Read now
Jennifer Munday, Mallik Greene, Eunice Chang, Ann Hartry, Tingjian Yan & Michael S. Broder. (2019) Early initiation of long-acting injectable antipsychotic treatment is associated with lower hospitalization rates and healthcare costs in patients with schizophrenia: real-world evidence from US claims data. Current Medical Research and Opinion 35:7, pages 1231-1239.
Read now
Read now
Dominic Pilon, Tony B. Amos, Guillaume Germain, Marie-Hélène Lafeuille, Patrick Lefebvre & Carmela J. Benson. (2017) Treatment persistence and hospitalization rates among patients with schizophrenia: a quasi-experiment to evaluate a patient information program. Current Medical Research and Opinion 33:4, pages 713-721.
Read now
Read now
Pierre Chue & James Chue. (2016) A review of aripiprazole long-acting injection. Current Medical Research and Opinion 32:3, pages 441-452.
Read now
Read now
Leslie Citrome. (2016) Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil. Expert Review of Clinical Pharmacology 9:2, pages 169-186.
Read now
Read now
Rene S Kahn & Amalia Giannopoulou. (2015) The safety, efficacy and tolerability of Abilify Maintena for the treatment of schizophrenia. Expert Review of Neurotherapeutics 15:9, pages 969-981.
Read now
Read now
Andrea Fagiolini, Roberto Brugnoli, Guido Di Sciascio, Sergio De Filippis & Giuseppe Maina. (2015) Switching antipsychotic medication to aripiprazole: position paper by a panel of Italian psychiatrists. Expert Opinion on Pharmacotherapy 16:5, pages 727-737.
Read now
Read now
John M. Kane, Cathy Zhao, Brian R. Johnson, Ross A. Baker, Anna Eramo, Robert D. McQuade, Anna R. Duca, Raymond Sanchez & Timothy Peters-Strickland. (2015) Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis. Journal of Medical Economics 18:2, pages 145-154.
Read now
Read now
Sheng-Min Wang, Changsu Han, Soo-Jung Lee, Ashwin A Patkar, Prakash S Masand & Chi-Un Pae. (2014) Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection. Neuropsychiatric Disease and Treatment 10, pages 1605-1611.
Read now
Read now
Marie-Hélène Lafeuille, Jason Dean, Valerie Carter, Mei Sheng Duh, John Fastenau, Riad Dirani & Patrick Lefebvre. (2014) Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia. Current Medical Research and Opinion 30:8, pages 1643-1655.
Read now
Read now
Articles from other publishers (26)
José Manuel Olivares & Andrea Fagiolini. (2022) Long-Term Real-World Effectiveness of Aripiprazole Once-Monthly. Treatment Persistence and Its Correlates in the Italian and Spanish Clinical Practice: A Pooled Analysis. Frontiers in Psychiatry 13.
Crossref
Crossref
Chi-Un Pae, Changsu Han, Won-Myong Bahk, Soo-Jung Lee, Ashwin A. Patkar & Prakash S. Masand. (2021) Clinical Benefit and Utility of Switching to Aripiprazole Once Monthly in Patients with Antipsychotic Polypharmacy or Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study. Clinical Psychopharmacology and Neuroscience 19:2, pages 233-242.
Crossref
Crossref
Dalibor Karlović, Ante Silić, Danijel Crnković & Vjekoslav Peitl. (2020) Effects of aripiprazole long‐acting injectable antipsychotic on hospitalization in recent‐onset schizophrenia. Human Psychopharmacology: Clinical and Experimental 36:2.
Crossref
Crossref
José Manuel Olivares, Ana González-Pinto & Mario Páramo. (2021) Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study. European Psychiatry 64:1.
Crossref
Crossref
Anna Maria Szota & Aleksander Araszkiewicz. (2020) The effectiveness of long-term aripiprazole injections to a patient with paranoid schizophrenia: a case report. Current Problems of Psychiatry 21:3, pages 154-160.
Crossref
Crossref
Massimo Carlo Mauri, Alessandra Reggiori, Alessandro Minutillo, Gemma Franco, Chiara Di Pace, Silvia Paletta & Dario Cattaneo. (2020) Paliperidone LAI and Aripiprazole LAI Plasma Level Monitoring in the
Prophylaxis of Bipolar Disorder Type I with Manic Predominance. Pharmacopsychiatry 53:05, pages 209-219.
Crossref
Crossref
Valeria Latorre, Apostolos Papazacharias, Maria Lorusso, Gaetano Nappi, Paola Clemente, Antonia Spinelli, Giovanni Carrieri, Enrico D’Ambrosio, Michele Gattullo, Antonio Emmanuele Uva & Domenico Semisa. (2020) Improving the “real life” management of schizophrenia spectrum disorders by LAI antipsychotics: A one-year mirror-image retrospective study in community mental health services. PLOS ONE 15:3, pages e0230051.
Crossref
Crossref
Hiroyuki Kamei, Yuki Homma, Ippei Takeuchi, Genta Hajitsu, Kaori Tozawa, Masakazu Hatano, Aiko Fukui, Manako Hanya, Shigeki Yamada & Nakao Iwata. (2020) Acceptance of the Deltoid Muscle Injection of Aripiprazole Long-acting Injectable in the Patients with Schizophrenia. Clinical Psychopharmacology and Neuroscience 18:1, pages 49-57.
Crossref
Crossref
Chi-Un Pae, Changsu Han, Won-Myong Bahk, Soo-Jung Lee, Ashwin A. Patkar & Prakash S. Masand. (2020) Effectiveness and Tolerability of Switching to Aripiprazole Once Monthly from Antipsychotic Polypharmacy and/or Other Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study. Clinical Psychopharmacology and Neuroscience 18:1, pages 153-158.
Crossref
Crossref
Elisabeth HöwlerElisabeth Höwler. 2020. Kinder- und Jugendpsychiatrie für Gesundheitsberufe, Erzieher und Pädagogen. Kinder- und Jugendpsychiatrie für Gesundheitsberufe, Erzieher und Pädagogen
161
168
.
Sally Mustafa, Joanna Bougie, Maia Miguelez, Guerline Clerzius, Emmanouil Rampakakis, Jean Proulx & Ashok Malla. (2019) Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study. BMC Psychiatry 19:1.
Crossref
Crossref
Chiara Rapinesi, Georgios D. Kotzalidis, Lorenzo Mazzarini, Roberto Brugnoli, Stefano Ferracuti, Sergio De Filippis, Ilaria Cuomo, Gloria Giordano, Antonio Del Casale, Gloria Angeletti, Gabriele Sani & Paolo Girardi. (2019) Long-Acting Injectable (LAI) Aripiprazole Formulations in the Treatment of Schizophrenia and Bipolar Disorder: a Systematic Review. Clinical Drug Investigation 39:8, pages 713-735.
Crossref
Crossref
Tingjian Yan, Mallik Greene, Eunice Chang, Michael S Broder, Maëlys Touya, Jennifer Munday & Ann Hartry. (2019) Hospitalization risk factors in antipsychotic-treated schizophrenia, bipolar I disorder or major depressive disorder. Journal of Comparative Effectiveness Research 8:4, pages 217-227.
Crossref
Crossref
Salvatore Gentile. (2018) Safety concerns associated with second-generation antipsychotic long-acting injection treatment. A systematic update. Hormone Molecular Biology and Clinical Investigation 36:2.
Crossref
Crossref
Steven D. Targum, Robert Risinger, Yangchun Du, J. Cara Pendergrass, Hassan H. Jamal & Bernard. L. Silverman. (2017) Effect of patient age on treatment response in a study of the acute exacerbation of psychosis in schizophrenia. Schizophrenia Research 179, pages 64-69.
Crossref
Crossref
Timothy Peters-Strickland, Cathy Zhao, Pamela P. Perry, Anna Eramo, Phyllis M. Salzman, Robert D. McQuade, Brian R. Johnson & Raymond Sanchez. (2016) Effects of aripiprazole once-monthly on symptoms of schizophrenia in patients switched from oral antipsychotics. CNS Spectrums 21:6, pages 460-465.
Crossref
Crossref
Tomasz Zaprutko, Robert Göder, Krzysztof Kus, Lyudmyla Rakhman, Rostyslav Bilobryvka & Elżbieta Nowakowska. (2015) The Cost of Inpatient Care of Schizophrenia and Treatment Schedules Used in German Academic Center: Kiel. Psychiatric Quarterly 87:4, pages 595-603.
Crossref
Crossref
Georgia L. Stevens, Gail Dawson & Jacqueline Zummo. (2015) Clinical benefits and impact of early use of long‐acting injectable antipsychotics for schizophrenia. Early Intervention in Psychiatry 10:5, pages 365-377.
Crossref
Crossref
Richard E Hodgson, Ravindra B Belgamwar & Sally Walsh. (2016) Long-acting aripiprazole (depot) versus placebo for schizophrenia. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Chelsea N. Carr, Colleen P. Hall, Jennifer E. Roche-Desilets, Christopher J. Burant & Matthew A. Fuller. (2016) Evaluation of adherence in patients prescribed long-acting injectable antipsychotics: A comparison of biweekly versus monthly administered neuroleptics. Mental Health Clinician 6:5, pages 248-253.
Crossref
Crossref
S. Breit & G. Hasler. (2015) Chancen und Kontroversen von Depotantipsychotika in der Behandlung von Patienten mit SchizophrenieAdvantages and controversies of depot antipsychotics in the treatment of patients with schizophrenia. Der Nervenarzt 87:7, pages 719-723.
Crossref
Crossref
Elisabeth HöwlerElisabeth Höwler. 2016. Kinder- und Jugendpsychiatrie für Gesundheitsberufe, Erzieher und Pädagogen. Kinder- und Jugendpsychiatrie für Gesundheitsberufe, Erzieher und Pädagogen
133
138
.
Stephen R. SakladTiffany-Jade KreysStephanie Phan. (2015) Aripiprazole long-acting injectable (ABILIFY MAINTENA) for treatment of schizophrenia. Mental Health Clinician 5:4, pages 149-161.
Crossref
Crossref
L. Samalin, T. Charpeaud & P.-M. Llorca. (2014) Aripiprazole injectable à libération prolongée dans le traitement de maintenance de la schizophrénie. L'Encéphale 40:6, pages 487-494.
Crossref
Crossref
Sofia Brissos, Miguel Ruiz Veguilla, David Taylor & Vicent Balanzá-Martinez. (2014) The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Therapeutic Advances in Psychopharmacology 4:5, pages 198-219.
Crossref
Crossref
Matt Shirley & Caroline M. Perry. (2014) Aripiprazole (ABILIFY MAINTENA®): A Review of Its Use as Maintenance Treatment for Adult Patients with Schizophrenia. Drugs 74:10, pages 1097-1110.
Crossref
Crossref